UNSPSC 51203102: Ecallantide

This classification denotes a protease inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5Q6TZN2HNM. European Medicines Agency schedules Ecallantide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31283. Ecallantide generally arises in the molecular formula C305H442N88O91S8.

The term ECALLANTIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, No. 1, 2006, list 55.) Most nations, for tariff and trade purposes, schedule ecallantide under HS 29349990 and SITC 51579. As of Q4 2014, ECALLANTIDE remains US FDA's Preferred Term for this commodity. Ecallantide bears US NLM identifiers UMLS ID C1722685 and NCI Concept Code C65505.

UNSPSC 51203102 Ecallantide is a Commodity code for pharmaceutical products, though the recent state and local opportunities tagged under it reflect a broader range of pharmaceutical procurement activity—naloxone and drug deactivation systems, generic pharmaceuticals and over-the-counter products, medical and first aid supplies, and direct-to-manufacturer prescription programs. State and local governments are using this code to procure finished pharmaceutical products, medical supplies, and pharmaceutical distribution services for public health agencies, fire departments, and multistate cooperative purchasing programs. Issuing bodies include county health departments, municipal fire departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions.

Activity is concentrated in Florida, Texas, Minnesota, and through the multistate MMCAP vehicle serving state and local facilities across multiple states including Oregon. Representative recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, due July 26, 2023); the City of Tampa's IFB for medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000.00 and an SLBE set-aside with a 5 percent bid discount (26P00145, due March 13, 2026); the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (S1070000015802, due March 26, 2026); and the Texas Health and Human Services Commission's RFI for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (HHS0017013, due April 3, 2026). The range spans transactional purchases of finished goods at the commodity level through strategic pharmaceutical sourcing and distribution arrangement programs.